30 results about "Cognitive defects" patented technology

The present invention provides a benzoate salt of Formula I:Formula I is also known as 4-(5-methyloxazolo[4,5-b]pyridine-2-yl)-1,4-diazabicyclo[3.2.2]nonane. The benzoate salt of the invention is useful in the treatment of schizophrenia and Alzheimer's Disease. It is particularly of use in the treatment of cognitive deficits associated with schizophrenia, cognitive and attention deficit symptoms of Alzheimer's Disease, and neurodegeneration associated with Alzheimer's Disease.

The invention is based on the surprising discovery that as few as one episode of blast exposure increases the risk of CTE. Blast exposure is associated with chronic traumatic encephalopathy, impaired neuronal function, and persistent cognitive deficits in blast-exposed military veterans and experimental animals. Early diagnosis and assessment of risk permits physicians to prescribe treatment to reduce or slow progression of impairment before the onset of overt symptoms that become apparent decades after an initial insult or trauma to brain tissue. The invention provides methods and compositions for diagnosis and prognosis of individuals at risk of long term complications related to blast injury or concussive injury.

The present invention provides methods of treating cognitive deficits associated with mental retardation. The methods comprise combining cognitive training protocols and a general administration of phosphodiesterase 4 inhibitors.

This application describes method of treating dementia and cognitive deficits associated with dementia that involve administration of dihydrotetrabenazine, and isomers and / or pharmaceutically acceptable salts thereof.

The invention discloses a voltage sag reason identification method and system. The method comprises the steps of obtaining a to-be-identified key waveform containing a voltage sag event in the online voltage data; carrying out dimensionality reduction on the to-be-identified key waveform to obtain a feature vector of the to-be-identified key waveform; and obtaining the reason type of the voltage sag event according to the feature vector. According to the method, an original data-feature data mapping relationship is automatically established from the historical sample data based on an automatic encoder, so that the problem that the feature quantity is ignored due to the cognitive defects in the prior art is avoided, more feature information can be mined, and the recognition precision is further improved. The sag event waveform data is subjected to the dimensionality reduction through the automatic encoder to obtain the feature vector, and then the feature vector is input into the classifier to obtain the reason type of the voltage sag event, so that the calculation scale is effectively reduced, and the real-time performance of the online identification is provided.

Novel heterodimers of tetrahydroacridines and tetrahydroquinolinones are disclosed. The heterodimers are capable of acting as both acetylcholinesterase inhibitors and N-methyl-D-aspartate (NMDA) receptor antagonists. The heterodimers may be used to improve cognitive defects via treatment or prevention in both humans and non-humans.

The present invention relates to novel geminal substituted quinuclidine amide compounds, and pharmaceutical compositions of the same, that are suitable as agonists or partial agonists of α7-nAChR, and methods of preparing these compounds and compositions, and the use of these compounds and compositions in methods of maintaining, treating and / or improving cognitive function. In particular, methods of administering the compound or composition to a patient in need thereof, for example a patient with a cognitive deficiency and / or a desire to enhance cognitive function, that may derive a benefit therefrom.

The present invention relates to N-[(4-hydroxypiperidine-4- Base) methyl] pyridin-2 (1H)-one derivatives, their stereoisomers, their pharmaceutically acceptable salts and their solvates, and their preparation methods, and their use in the prevention or treatment of 5-HT system dysfunction Related central nervous system diseases such as depression, anxiety, cognitive deficits, mania, schizophrenia, pain, etc., or used as a tool drug to study 5-HT function and its 5-HT dysfunction related diseases, and pharmaceutical compositions containing these compounds. Each substituent in formula I is as described in the specification.

The invention relates to a cognitive impairment prediction method based on edge intelligence and multimode perception. According to the method, daily activities and abnormal behaviors of the elderly are monitored, recorded, analyzed and judged to assist in diagnosing whether the elderly suffer from early cognitive impairment or not; the method is beneficial to delaying the cognitive decline speedthrough various rehabilitation training means of the mobile terminal after the cognitive impairment is accurately analyzed, so that effective service and help are provided for the health and happinessof old people. Internet of Things data is acquired through various acquisition devices, and after processing and analysis are performed at an edge end, a result is returned to the cloud database; mining long-term abnormal behaviors by adopting a historical behavior analysis method, and carrying out pre-diagnosis on early cognitive impairment; APPs capable of providing corresponding cognitive training for different types of cognitive defects are developed to assist patients in delaying cognitive decline.

The present invention relates to a neurotrophic peptide having an amino acid sequence of VGDGGLFEKKL (SEQ ID NO:1) and alternatively comprising an adamantyl group at the C- and / or N-terminal end. The neurotrophic peptide can rescue cognition, correct impairments in neural cell proliferation and synaptic plasticity, and thus address the cognitive defects associated with Down syndrome.

Provided are methods for treating and / or reducing the symptoms of a neurological or neurodevelopmental disease or disorder characterized by ectopic expression of certain ion channels, in particular, the Nav1.8 subtype SCN10a sodium channel, or the KCNQ1 potassium channel, in neuronal cells of the central nervous system (CNS) of a subject by administering to a subject in need an antagonist of one or both of these ion channels, and in particular, an antagonist of SCN10a, to block, reduce, or suppress the aberrant CNS neuronal ion channel expression and / or activity and normalize behavioral and cognitive defects associated with the neurological and neurodevelopmental disease or disorder, so as to treat and / or reduce the symptoms of the neurological or neurodevelopmental disease or disorder. Examples of such diseases or disorders that may be treated by the described methods include, for example, Pitt-Hopkins Syndrome (PTHS), autism, autism spectrum disorder, schizophrenia, 18q syndrome and the like.

The present invention relates to a neurotrophic peptide having an amino acid sequence of VGDGGLFEKKL (SEQ ID NO: 1) and alternatively comprising an adamantyl group at the C- and / or N-terminal end. The neurotrophic peptide can rescue cognition, correct impairments in neural cell proliferation and synaptic plasticity, and thus address the cognitive defects associated with Alzheimer's disease.

The invention relates to the application of icariin in the preparation of a medicine for preventing and treating Alzheimer's disease. According to the invention, experiments such as a Morris water maze experiment, a Western blot experiment, an HE staining method and the like are carried out in an SAMP8 model mouse; it is proved that learning and memory disorder of SAMP8 mice can be reversed afterintragastric administration of ICA, icariin can down-regulate expression of BACE1 so as to reduce deposition of cytotoxic A beta 1-42. Besides, icariin can improve cognitive defects by increasing theexpression of anti-apoptotic protein Bcl-2, reducing the expression of pro-apoptotic protein Bax and remarkably increasing the ratio of Bcl-2 to Bax, so that neuronal apoptosis is inhibited, and neurons are protected. The invention provides further evidences for the clinical curative effect of icariin on Alzheimer's disease.

The present disclosure provides methods for treating one or more of cognitive deficits or cognitive impairments associated with or caused by mild brain injuries, chemotherapy treatment, chemotherapy medication, post-chemotherapy cognitive impairment (PCCI), chemo brain, and other disorders arising from cognitive dysfunction in a subject by administering to the subject an effective amount of a composition comprising ghrelin or a ghrelin variant.

The present disclosure provides methods of treating Alzheimer's Disease (AD) and rescuing cognitive deficits associated with AD in a subject having an apoE4 / 4 genotype, by administering a therapeutically effective amount of the loop-diuretic bumetanide to the subject. Also disclosed are kits for performing the method, including one or more doses of a bumetanide formulation; and which may also include instructions for treating a patient having an apoE4 / 4 genotype by administering bumetanide, and / or instructions and reagents for testing / identifying a subject having an apoE4 / 4 genotype.

The invention provides a method for presenting a cognitive diagnosis report of English reading of college students, and the method comprises the steps: firstly carrying out the data calculation of cognitive attributes of examinees through a G-DINA model, and carrying out the objective evaluation; displaying the score and the score score level of the testee, and providing information about how to read the diagnosis report; providing an examinee answer column and a standard answer column, and displaying the cognitive attributes mastered / unmastered by the examinee by using a 1 / 0 dichotomy; providing examinee mastering and unmastering reading cognition attribute names and detailed definitions thereof; providing hyperlinks according to cognitive attribute mastering conditions of examinees, andcarrying out targeted remedial training on the examinees. According to the method, detailed explanation of each cognitive attribute is provided, an examinee can know the cognitive defects existing inthe reading process of the examinee, finally, targeted guidance suggestions are provided for students in a hyperlink mode, next-stage practice of the students is automatically associated, and the method has a targeted guidance effect on improvement of the reading ability of the students.

The invention relates to an intelligent auxiliary device and an application method thereof, in particular to an intelligent auxiliary device beneficial to people with visual and / or cognitive impairment and an application method of the intelligent auxiliary device, especially for patients with Alzheimer's disease. The auxiliary device comprises a pair of glasses, wherein a main control module, a language module, an optical sensing module and a control key module are arranged on the glasses; the main control module is connected with the voice module and the light conduction module; the main control module comprises a central processing module, a storage module, a voice module and a wireless module; the optical sensing module is provided with a camera and is mainly used for collecting information, can carry out information delivery and provides visual assistance for a patient; the voice module is mainly a bone conduction device and is mainly used for language playing of information and providing audible assistance for the patient; and the control key module is mainly used for facilitating assistance seeking operation of the patient. The intelligent auxiliary glasses and the application method thereof mainly have the beneficial effects that the intelligent auxiliary glasses have the functions of video shooting and releasing, reverse playing, telephone communication, positioning andnavigation, voice reminding, voice information recording, language information intelligent extraction and the like, can provide visual and auditory auxiliary help for patients with cognitive defects,and is particularly suitable for patients with Alzheimer's disease.

The present disclosure provides methods of treating Alzheimer's Disease (AD) and rescuing cognitive deficits associated with AD in a subject having an apoE4 / 4 genotype, by administering a therapeutically effective amount of the loop-diuretic bumetanide to the subject. Also disclosed are kits for performing the method, including one or more doses of a bumetanide formulation; and which may also include instructions for treating a patient having an apoE4 / 4 genotype by administering bumetanide, and / or instructions and reagents for testing / identifying a subject having an apoE4 / 4 genotype.

The invention relates to the technical field of the neurology department, in particular to a medicine for treating neurasthenia. The medicine is prepared from components in percentage by mass as follows: 2%-4% of trimetozine, 1%-5% of midecamycin, 30%-40% of nabumetone, 15%-17% of taurine, 2%-6% of ketotifen, 23%-25% of catechol, 3%-5% of nicotinamide, 1%-3% of oleanolic acid, 1.5%-2.5% of quetiapine and 2.5%-11.5% of loxoprofen. The invention also discloses a preparation method of the medicine. The medicine comprises the steps as follows: step 1, preparing materials; step 2, drying and grinding the materials into powder; step 3, performing crushing treatment; step 4, preparing an ethanol solution; step 5, performing concentration and drying; step 6, extracting the medicine. The medicine can effectively improve organism functions and enhance immunity, has significant effects on the neurasthenia, has no toxic or side effects on the human body, can relieve anxiety and cognitive defect symptoms and has effects of clearing heat, reducing internal heat, regulating flow of vital energy and dredging collaterals.

The invention relates to a novel antagonist and / or an inverse agonist of cannabinoide receptor-1 (cannabinoid receptor type 1, CB1) with a structural formula shown as a formula (I), a preparation method and an application thereof. In the structural formula, R1, R2, R3, R4, R5, R6, R7 and R8 are defined as the specification sheet. The compound of the invention can be used for treating, preventing or relieving diseases mediated by the CB1 receptor. The compound and pharmaceutically acceptable salt thereof can also be used for treating, preventing or relieving adiposity, diabetes mellitus, drug dependence, cognitive defect, nervous system diseases, diseases of gastrointestinal tract and cirrhosis.

The invention relates to a novel antagonist and / or an inverse agonist of cannabinoide receptor-1 (cannabinoid receptor type 1, CB1) with a structural formula shown as a formula (I), a preparation method and an application thereof. In the structural formula, R1, R2, R3, R4, R5, R6, R7 and R8 are defined as the specification sheet. The compound of the invention can be used for treating, preventing or relieving diseases mediated by the CB1 receptor. The compound and pharmaceutically acceptable salt thereof can also be used for treating, preventing or relieving adiposity, diabetes mellitus, drug dependence, cognitive defect, nervous system diseases, diseases of gastrointestinal tract and cirrhosis.

The present invention relates to a neurotrophic peptide having an amino acid sequence of VGDGGLFEKKL (SEQ ID NO:1) and alternatively comprising an adamantyl group at the C- and / or N-terminal end. The neurotrophic peptide can rescue cognition, correct impairments in neural cell proliferation and synaptic plasticity, and thus address the cognitive defects associated with Down syndrome.

The present invention relates to a method of use of a composition comprising an autophagy enhancement compound for treating neurodegenerative diseases. In particular, the said composition is used to treat the neural condition of synaptic dysfunction. Such neurodegenerative diseases include Parkinson's disease, Alzheimer's disease, Huntington's disease, Frontotemporal dementia with parkinsonism-17 (FTDP-17), Pick disease (PiD), Progressive supranuclear palsy (PSP), Corticobasal degeneration (CBD) and Cerebral amyloid angiopathy.